Vertex Pharmaceuticals Incorporated (VRTX)
-NasdaqGS | Prev Close: | 77.87 |
|---|
| Open: | N/A |
|---|
| Bid: | N/A |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 92.48 |
|---|
| Beta: | 0.15 |
|---|
| Next Earnings Date: | 29-Jul-13 |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 38.44 - 87.47 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 2,466,690 |
|---|
| Market Cap: | 17.24B |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -2.38 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Vertex Pharmaceuticals Moves Up In Market Cap Rank, Passing Intuitat Forbes(Tue, Jun 18)
- Vertex Completes Redemption of Convertible Senior Subordinated NotesBusiness Wire(Tue, Jun 18)
- 3 High Risk Hot Stocks To Watchat TheStreet(Mon, Jun 17)
- Gilead's Potential Megablockbuster Raises the Barat Motley Fool(Mon, Jun 17)
- Commit To Purchase Vertex Pharmaceuticals At $55, Earn 13.3%at Forbes(Fri, Jun 14)
- Vertex CF data positive, says RBC Capitaltheflyonthewall.com(Fri, Jun 14)
- These Mutated Cystic Fibrosis Cells Are Worth Billions to Vertex Pharmaat TheStreet(Thu, Jun 13)
- Inside HCV: An Interview with Janssenat Motley Fool(Thu, Jun 13)
- Game-Changing Hep C Pill Closer to Approvalat Motley Fool(Tue, Jun 11)
- Vertex Pharmaceuticals (VRTX): Today's Featured Drugs Laggardat TheStreet(Tue, Jun 11)
- Vertex Pharmaceuticals Incorporated Presents at Goldman Sachs 34th Annual Global Healthcare Conference, Jun-11-2013 10:00 AMat Seeking Alpha(Tue, Jun 11)
- SMC posts decision on Kalydeco resubmission to websitetheflyonthewall.com(Tue, Jun 11)
- Vertex's Roadmap to $10 Billion in Cystic Fibrosis Drug Salesat TheStreet(Tue, Jun 11)
- 5 Drugs Stocks Dragging The Industry Downat TheStreet(Mon, Jun 10)
- [video] Biotech's Next Big Thing: Vertexat TheStreet(Thu, Jun 6)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 12.17 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -2.15 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.17 |
|---|
| Mean Recommendation*: | 1.9 |
|---|
| PEG Ratio (5 yr expected): | -5.75 |
|---|
Business Summary
Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases.
View More